REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy shows promise against Tough-to-Treat blood cancer
Disease control CompletedThis study tested the safety and early effectiveness of two different drug combinations for people with an aggressive type of lymphoma that had returned or stopped responding to prior treatments. It involved 53 patients who were not eligible for stem cell transplant. The main goa…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Apr 04, 2026 00:05 UTC
-
Scientists test new combo attack on stubborn blood cancers
Disease control CompletedThis early-stage study tested a new combination of two drugs, lenalidomide and blinatumomab, for people with non-Hodgkin lymphoma that had come back or stopped responding to other treatments. The main goal was to find the safest and most effective dose of the drugs when used toge…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New pill tested for Tough-to-Treat blood cancer
Disease control CompletedThis study tested whether a pill called zanubrutinib could help adults with a specific type of aggressive lymphoma that had returned or stopped responding to prior treatments. The trial focused on people whose cancer had a particular genetic change (CD79B mutation). Participants …
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New hope for toughest lymphomas: experimental combo targets Cancer's repair system
Disease control CompletedThis early-stage study tested a new combination of drugs for patients with aggressive lymphomas that have come back or not responded to standard treatments. The main goal was to find the safest dose of a drug called olaparib when given with a powerful chemotherapy regimen before …
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New drug aims to boost Cancer-Fighting CAR-T cells
Disease control CompletedThis study tested a drug called NT-I7 in patients with aggressive lymphoma that returned after CAR-T therapy. The main goal was to find a safe dose and see if NT-I7 could help the CAR-T cells last longer and fight the cancer better. The trial involved 17 adults who had already re…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC